کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5588719 | 1404571 | 2016 | 31 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Maintenance of cytosolic calcium is crucial to extend l-arginine therapeutic benefits during continuous dosing
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
PBSO2•–CDBaminophenyl fluoresceinAPFCaMKIIHUVECNOSAMPKAMP-activated protein kinase - AMP-پروتئین کیناز فعال شده استCa2+ - Ca2 +l-NAME - L-NAMEl-NG-Nitroarginine methyl ester - L-NG-Nitroarginine متیل استرONOO− - ONOO-l-arginine - آرژینین الendothelial nitric oxide - اکسید نیتریک آندوتلیالBAPTA - بیایپیتیایTolerance - تلرانس Oxidative stress - تنش اکسیداتیوHuman umbilical vein endothelial cells - سلول های اندوتلیالی ورید ناف انسانSuperoxide - سوپر اکسیدPhosphate-buffered saline - محلول نمک فسفات با خاصیت بافریnitric oxide synthase - نیتریک اکسید سنتازcalmodulin-dependent protein kinase - پروتئین کیناز وابسته به کالمدولینPeroxynitrite - پروکسی نیتریتTherapeutic efficacy - کارآیی درمانیCalcium channel - کانال کلسیمCalcium - کلسیم
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
علوم غدد
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
The therapeutic benefits associated with short-term l-arginine supplementation are lost during continuous dosing. AMP-activated protein kinase (AMPK) functional modulation has been correlated with l-arginine therapeutic effectiveness, and with tolerance development during continuous supplementation. However, the metabolic link that is responsible for AMPK functional modulation during continuous l-arginine exposure is currently not known. To explore this, we incubated HUVECs for 7 days with 100 μmol/L l-arginine, in the presence or absence of other agents; and monitored their effects for eNOS function, and on tolerance sparing effects (viz, cellular glucose accumulation, and oxidative stress). HUVEC co-incubation with 100 μmol/L l-arginine and â¤1200 mg/mL calcium (Ca2+) for 7 days avoided tolerance development, with an at least 1-fold increase in the eNOS and AMPK functional activity; and an 1-fold increase in overall cellular glucose uptake. The overall cellular cytosolic Ca2+was below 200 nmol/L, with no change in cellular glucose and superoxide/peroxynitrite (O2
- â/ONOOâ) level from control. However, tolerance sparing effects of at least 70% decrease in eNOS and AMPK functional response, with an 1-fold reduction in glucose uptake, and at least 2-fold increase in O2
- â/ONOOâ were observed in cells exposed for 7 days to 100 μmol/L l-arginine at Ca2+co-incubation concentration of >1200 mg/mL. The >1200 mg/mL Ca2+ co-incubation condition, also improved the overall cellular Ca2+to >200 nmol/L. Similar tolerance response was observed in cells co-treated with 100 μmol/L l-arginine and â¤1200 mg/mL Ca2+ in the presence of Ca2+ influx inhibitor (20 μmol/L 1,2-bis(o-aminophenoxy)ethane-N,N,Nâ²,Nâ²-tetra acetic acid), or eNOS activity inhibitor (30 μmol/L l-NG-nitroarginine methyl ester). No tolerance response was seen in cells incubated for 7 days with 100 μmol/L l-arginine and â¤1200 mg/mL Ca2+; even in the presence of the inhibitor for cellular glucose induction (30 μmol/L 5-chloro-2-(n-(2,5-dichlorobenzenesulfonamide))-benzoxazole). The present study thus provides the first definitive evidence that shows the need to maintain cytosolic Ca2+ within a threshold limit of less than 200 nmol/L to extend l-arginine therapeutic efficacy during continuous dosing, without any potential tolerance development.
- â/ONOOâ) level from control. However, tolerance sparing effects of at least 70% decrease in eNOS and AMPK functional response, with an 1-fold reduction in glucose uptake, and at least 2-fold increase in O2
- â/ONOOâ were observed in cells exposed for 7 days to 100 μmol/L l-arginine at Ca2+co-incubation concentration of >1200 mg/mL. The >1200 mg/mL Ca2+ co-incubation condition, also improved the overall cellular Ca2+to >200 nmol/L. Similar tolerance response was observed in cells co-treated with 100 μmol/L l-arginine and â¤1200 mg/mL Ca2+ in the presence of Ca2+ influx inhibitor (20 μmol/L 1,2-bis(o-aminophenoxy)ethane-N,N,Nâ²,Nâ²-tetra acetic acid), or eNOS activity inhibitor (30 μmol/L l-NG-nitroarginine methyl ester). No tolerance response was seen in cells incubated for 7 days with 100 μmol/L l-arginine and â¤1200 mg/mL Ca2+; even in the presence of the inhibitor for cellular glucose induction (30 μmol/L 5-chloro-2-(n-(2,5-dichlorobenzenesulfonamide))-benzoxazole). The present study thus provides the first definitive evidence that shows the need to maintain cytosolic Ca2+ within a threshold limit of less than 200 nmol/L to extend l-arginine therapeutic efficacy during continuous dosing, without any potential tolerance development.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Nutrition Research - Volume 36, Issue 10, October 2016, Pages 1114-1120
Journal: Nutrition Research - Volume 36, Issue 10, October 2016, Pages 1114-1120
نویسندگان
Srinidi Mohan, Lisa Harding,